HPGDS inhibitor 3

HPGDS inhibitor 3

• CAS Number: 2255311-93-2
• UNSPSC Description: HPGDS inhibitor 3 is an orally active and highly potent peripherally restricted hematopoietic prostaglandin D synthase (H-PGDS) inhibitor with IC50 value of 9.4 nM and EC50 of 42 nM, respectively. HPGDS inhibitor 3 exhibits good selectivity, good pharmacokinetic parameters in mouse, rat, and dog, and no CNS toxicity. HPGDS inhibitor 3 has anti-inflammatory activity[1].
• Target Antigen: PGE synthase
• Type: Reference compound
• Related Pathways: Immunology/Inflammation
• Applications: COVID-19-immunoregulation
• Field of Research: Inflammation/Immunology
• Assay Protocol: https://www.medchemexpress.com/hpgds-inhibitor-3.html
• Solubility: 10 mM in DMSO
• Smiles: CC(O)([C@H]1CC[C@@H](CC1)NC(C2=CC3=CC=C(N=C3N=C2)C4CC4)=O)C
• Molecular Weight: 353.46
• References & Citations: [1]Cadilla R, Deaton DN, Do Y, et al. The exploration of aza-quinolines as hematopoietic prostaglandin D synthase (H-PGDS) inhibitors with low brain exposure. Bioorg Med Chem. 2020;28(23):115791.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported